Please login to the form below

Not currently logged in
Email:
Password:

Nycomed markets Bonviva drug in Asia

Nycomed has become marketing authorisation holder of osteoporosis treatment Bonviva in key Asia-Pacific countries

Nycomed has completed the transfer of marketing authorisation approval for osteoporosis treatment Bonviva (Ibandronate) in a number of key Asia Pacific markets.

The licensing and supply agreement with Roche covers China, Hong Kong, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan and Vietnam, with a future option to commercialise Bonviva in additional Asia Pacific territories.

Under the terms of the deal, Nycomed will hold marketing authorisation holder in all the licensed territories. Bonviva is a bisphosphonate used in the treatment of osteoporosis in post-menopausal women.

Financial details of the agreement were not disclosed.

Guido Oelkers, executive vice-president of commercial operations, said: "The in-licensing of Bonviva from Roche is another important step towards Nycomed's expansion in the Asia Pacific region and demonstrates our growing attraction as a marketing partner for leading companies and brands in these dynamic countries.”

Nycomed recently opened offices in China, South Korea, Indonesia, Malaysia and the Philippines.

15th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics